Metabolomic Profile in Breastfed Late Preterm Infants

NCT ID: NCT06052592

Last Updated: 2024-09-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

54 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-03-01

Study Completion Date

2023-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Exclusive breast milk is recommended from birth to 6 months of life to promote the development of a balanced intestinal microbiota. Human milk provides several bioactive components, from natural probiotics such as Bifidobacterium spp. and Lactobacillus spp., to their metabolites which colonize the intestine of the newborn. However, if breast milk is not available or insufficient, it is used formula milk as a substitute. Infant formula can be supplemented with postbiotics to promote maturation of immune, metabolic and microbial components, similar to breast milk. Postbiotics are preparations composed of both microbial constituents and their metabolites, produced during fermentation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A balanced nutrition starting from early childhood significantly influences growth and psychomotor development. Exclusive breast milk is the recommended nutritional choice from birth to 6 months of life, as it guarantees everything necessary for growth, maturation, protection from infections, promoting the development of a balanced intestinal microbiota. Several prenatal and perinatal factors including the type of delivery, the use of antibiotics, diet and other environmental factors, can influence the microbial colonization of the newborn. Thus, it is generally accepted that the gut microbiota of the healthy, full-term, vaginally born, breastfed infant is the gold standard for a favorable microbial composition in the early years of life. Human milk provides several bioactive components, from natural probiotics such as Bifidobacterium spp. and Lactobacillus spp., to their metabolites ("natural postbiotics"), which colonize the intestine of the newborn. These metabolites regulate the development of the immune system and attenuate the inflammatory processes. However, if breast milk is not available or insufficient to meet the nutritional needs of the infant, formula milk is proposed and used as a substitute. Given the benefits, it is essential that infant formula is as close to human milk as possible, providing bioactive substances that target gut and immune system health. Current research focuses on optimizing artificial formulas, with the aim of resembling human milk in composition and functionality, with some on the market already including probiotics, prebiotics, synbiotics and postbiotics. However, it still remains to be clarified which is the best formulation and the exact consequences on the immune, metabolic and microbial system of the newborn. In particular, postbiotics are preparations composed of both microbial constituents and their metabolites, produced during fermentation. It has already been highlighted in the literature that the enrichment of formula milk with post-biotics would seem to offer advantages for feeding term infants. Furthermore, it promotes an immune, metabolic and microbial component maturation, similarly to human milk, thus making postbiotic supplements very promising and interesting in the nutrition of newborns and infants.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Formula Milk Breast Milk Collection Postbiotic Supplemented Formula Milk

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A

Newborns fed with formula milk supplemented with 20 mg/day of fermented FOS from Lactobacillus paracasei strain CNCM I-5220 and Vitamin D (0.5 ml of SMART D3 MATRIX)

Milk

Intervention Type OTHER

Newborns will be fed with breast milk, formula milk or postbiotic formula milk

Group B

Newborns fed with formula milk

Milk

Intervention Type OTHER

Newborns will be fed with breast milk, formula milk or postbiotic formula milk

Group C

Newborns fed with exclusive breast milk

Milk

Intervention Type OTHER

Newborns will be fed with breast milk, formula milk or postbiotic formula milk

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Milk

Newborns will be fed with breast milk, formula milk or postbiotic formula milk

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Weight appropriate to gestational age (percentiles \>10th and \<90th)
* Written informed consent

Exclusion Criteria

* Cardiological diseases
* Liver disease
* Gastrointestinal diseases with malabsorption
* Endocrinological diseases
* Perinatal infections
* Metabolic and genetic diseases
* Born to mothers with endocrinological and metabolic diseases
* Withdrawal of informed consent
Minimum Eligible Age

34 Weeks

Maximum Eligible Age

37 Weeks

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Salerno

OTHER

Sponsor Role collaborator

Ospedale Buon Consiglio Fatebenefratelli

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Giuseppe De Bernardo

Head of Department of Woman and Child

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Giuseppe De Bernardo, MD

Role: PRINCIPAL_INVESTIGATOR

Ospedale Buon Consiglio Fatebenefratelli

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Pharmacy, University of Salerno

Salerno, Naples, Italy

Site Status

Department of Woman and Child, Buon Consiglio Fatebenefratelli Hospital

Napoli, Napoli, Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1680/CE Lazio 1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.